Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Doumas

Showing results (101-110 of 382) with videos related to

Pageof 39
Sort By:
Clinical and Molecular Hepatology|May 31, 2019
Serum leptin in non-alcoholic fatty liver disease: Ambiguous clinical implications concerning cardiovascular diseaseDimitrios Patoulias, Konstantinos Imprialos, Konstantinos Stavropoulos, et al.
Acta Diabetologica|August 21, 2020
Diabetes mellitus and SARS-CoV-2-related mortality: the impact of acute hyperglycemic crises and some further considerationsDimitrios Patoulias, Alexandra Katsimardou, Christodoulos Papadopoulos, et al.
The American Journal of Cardiology|August 17, 2022
Updated Meta-Analysis Assessing the Cardiovascular Efficacy of TirzepatideDimitrios Patoulias, Christodoulos Papadopoulos, Nikolaos Fragakis, et al.
Expert Opinion on Pharmacotherapy|August 13, 2022
Dual sodium-glucose cotransporter (SGLT) 1/2 versus pure SGLT2 inhibitors: two distinct drug categories or one class with multiple faces?Theocharis Koufakis, Michael Doumas, Pantelis Zebekakis, et al.
Reviews in Cardiovascular Medicine|July 30, 2024
Exercise, Erectile Dysfunction and Co-Morbidities: "The Good, the Bad and the Ugly"Dimitris Patoulias, Alexandra Katsimardou, Konstantinos Imprialos, et al.
Nefrologia|December 9, 2022
Renal effects of sodium-glucose co-transporter-2 inhibitors in patients with heart failure with reduced or preserved ejection fractionDimitrios Patoulias, Christodoulos Papadopoulos, Asterios Karagiannis, et al.
The American Journal of Cardiology|January 20, 2022
Meta-Analysis Assessing the Impact of Previous Heart Failure and Chronic Kidney Disease on the Cardiovascular Efficacy of Glucagon-Like Peptide-1 Receptor AgonistsDimitrios Patoulias, Christodoulos Papadopoulos, Asterios Karagiannis, et al.
Clinical Rheumatology|August 25, 2021
Janus kinase inhibitors and major COVID-19 outcomes: time to forget the two faces of Janus! A meta-analysis of randomized controlled trialsDimitrios Patoulias, Michael Doumas, Christodoulos Papadopoulos, et al.
Kardiologia Polska|July 22, 2021
Cardiovascular drug therapy and surrogate COVID-19 outcomes: which is the impact of the "miraculous" sodium-glucose co-transporter-2 inhibitors?Dimitrios Patoulias, Christodoulos Papadopoulos, George Kassimis, et al.
Saudi Journal of Kidney Diseases and Transplantation : an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia|December 23, 2025
Effects of Long-Term Use of Sodium-Glucose Co-Transporter-2 Inhibitors on Proteinuria and Renal Function in Patients with Type 2 Diabetes Mellitus without Chronic Kidney Disease during the COVID-19 PandemicDimitrios Patoulias, Christodoulos Papadopoulos, Asterios Karagiannis, et al.
Pageof 39

Showing results (101-110 of 382) with videos related to

Sort By:
Pageof 39
Clinical and Molecular Hepatology|May 31, 2019
Serum leptin in non-alcoholic fatty liver disease: Ambiguous clinical implications concerning cardiovascular diseaseDimitrios Patoulias, Konstantinos Imprialos, Konstantinos Stavropoulos, et al.
Acta Diabetologica|August 21, 2020
Diabetes mellitus and SARS-CoV-2-related mortality: the impact of acute hyperglycemic crises and some further considerationsDimitrios Patoulias, Alexandra Katsimardou, Christodoulos Papadopoulos, et al.
The American Journal of Cardiology|August 17, 2022
Updated Meta-Analysis Assessing the Cardiovascular Efficacy of TirzepatideDimitrios Patoulias, Christodoulos Papadopoulos, Nikolaos Fragakis, et al.
Expert Opinion on Pharmacotherapy|August 13, 2022
Dual sodium-glucose cotransporter (SGLT) 1/2 versus pure SGLT2 inhibitors: two distinct drug categories or one class with multiple faces?Theocharis Koufakis, Michael Doumas, Pantelis Zebekakis, et al.
Reviews in Cardiovascular Medicine|July 30, 2024
Exercise, Erectile Dysfunction and Co-Morbidities: "The Good, the Bad and the Ugly"Dimitris Patoulias, Alexandra Katsimardou, Konstantinos Imprialos, et al.
Nefrologia|December 9, 2022
Renal effects of sodium-glucose co-transporter-2 inhibitors in patients with heart failure with reduced or preserved ejection fractionDimitrios Patoulias, Christodoulos Papadopoulos, Asterios Karagiannis, et al.
The American Journal of Cardiology|January 20, 2022
Meta-Analysis Assessing the Impact of Previous Heart Failure and Chronic Kidney Disease on the Cardiovascular Efficacy of Glucagon-Like Peptide-1 Receptor AgonistsDimitrios Patoulias, Christodoulos Papadopoulos, Asterios Karagiannis, et al.
Clinical Rheumatology|August 25, 2021
Janus kinase inhibitors and major COVID-19 outcomes: time to forget the two faces of Janus! A meta-analysis of randomized controlled trialsDimitrios Patoulias, Michael Doumas, Christodoulos Papadopoulos, et al.
Kardiologia Polska|July 22, 2021
Cardiovascular drug therapy and surrogate COVID-19 outcomes: which is the impact of the "miraculous" sodium-glucose co-transporter-2 inhibitors?Dimitrios Patoulias, Christodoulos Papadopoulos, George Kassimis, et al.
Saudi Journal of Kidney Diseases and Transplantation : an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia|December 23, 2025
Effects of Long-Term Use of Sodium-Glucose Co-Transporter-2 Inhibitors on Proteinuria and Renal Function in Patients with Type 2 Diabetes Mellitus without Chronic Kidney Disease during the COVID-19 PandemicDimitrios Patoulias, Christodoulos Papadopoulos, Asterios Karagiannis, et al.
Pageof 39